While historical data suggest venture capital rounds will eventually dip below the peak years, biopharma financings completed in recent months indicate the dollars are continuing to climb in 2021. A maturing industry, the high potential of cell and gene therapy products, the advancing technologies of artificial intelligence and machine learning, as well as an eager financial community, are all responsible for the ever-increasing availability of private money.
While historical data suggest venture capital rounds will eventually dip below the peak years, biopharma financings completed in recent months indicate the dollars are continuing to climb in 2021.
The rapid development of mRNA vaccines to combat COVID-19 has highlighted the importance of this single-stranded molecule. Although there have been some costly developmental bumps along the way, interest in RNA-targeted therapies is once again surging.
After working 24/7 to develop a COVID-19 vaccine in a historic timeframe and scale up manufacturing at an unprecedented rate, some vaccine manufacturers are now facing what appears to be a concerted Russian misinformation campaign akin to those used in the last two U.S. presidential campaigns.
RSS
